Übersichtsarbeit
Uwe Wollina
Botulinum Toxin Typ A: Anabotulinum A, Onabotulinum A und Incabotulinum A – Unterschiede und der gesunde Menschenverstand
Botulinum Toxin Type A: Anabotulinum A, Onabotulinum A, and Incabotulinum A – Differences and Common Sense
Keywords | Summary | Correspondence | Literature
Keywords
anabotulinum, Botulinum toxin type A, incabotulinum, onabotulinum, prodrugs
Schlüsselworte
Anabotulinum, Botulinumtoxin Typ A, Incabotulinum, Onabotulinum, Prodrugs
Summary
Three different brands of botulinum toxin type A are registered in Europe and the USA – ana- ona-, and incabotulinum A. This review described differences of the products. Since in all three products the active compound is identical, i.e. 50kDa chain, the commercially available products may be considered as prodrugs. Their efficacy and safety is comparable when used in equivalent dosages.
Zusammenfassung
Drei unterschiedliche Marken von Botuliniumtoxin A sind in Europa und den USA zugelassen – Ana-, Ona- und Incabotulinum A. Diese Übersicht stellt Unterschiede in den Produkten dar. Da bei allen Marken die aktive Substanz die 50 kDa Kette darstellt, können die kommerziellen Produkte als Prodrugs verstanden werden. Ihre Wirksamkeit und ihr Sicherheitsprofil sind bei äquivalenten Dosen vergleichbar.
Leider haben Sie sich nicht eingeloggt, um den Beitrag lesen zu können. Bitte loggen Sie sich ein oder beantragen Sie Ihre Zugangsberechtigung. Vielen Dank. Weitere Informationen finden Sie hier>
Korrespondenz-Adresse
Prof. Dr.med. Uwe Wollina
Department of Dermatology and Allergology
Academic Teaching Hospital Dresden-Friedrichstadt
Friedrichstrasse 41
D-01067 Dresden
Wollina-uw@khdf.de
Literatur
1. Wollina U (2008) Botulinum toxin: Non-cosmetic indications and possible mechanisms of action. J Cutan Aesthet Surg 1: 3-6.
2. Pickett A, Perrow K (2011) Towards new uses of botulinum toxin as a novel therapeutic tool. Toxins (Basel) 3: 63-81.
3. Fernandez-Salas E, Ho H, Garay P, Steward LE, Aoki KR (2004) Is the light chain subcellular localization an important factor in botulinum toxin duration of action? Mov Disord 19: S23–S34.
4. Eisele KH, Fink K, Vey M, Taylor HV (2011) Studies on the dissociation of botulinum neurotoxin type A complexes. Toxicon 57: 555-65.
5. Carruthers A, Carruthers (2008) Botulinum toxin products overview. Skin Therapy Lett 13: 1-4.
6. Lowe NJ, Lowe P(2012) Botulinum toxins for facial lines: a concise review. Dermatol Ther (Heidelberg) 2: 14.
7. Rystedt A, Karlqvist M, Bertilsson M, Naver H, Swartling C (2013) Effect of botulinum toxin concentration on reduction in sweating: A randomized, double-blind study. Acta Derm Venereol 93: 674-8.
8. Chung ME, Song DH, Park JH (2012) Comparative study of biological activity of four botulinum toxin type A preparations in mice. Dermatol Surg 39: 155-64.
9. Jandhyala R. Relative potency of incobotulinumtoxin A vs onabotulinumtoxin A a meta-analysis of key evidence. J Drugs Dermatol 11: 731-6.
10. Hexsel D, Brum C, do Prado DZ, Soirefmann M, Rotta FT, Dal'Forno T, et al. (2012) Field effect of two commercial preparations of botulinum toxin type A: a prospective, double-blind, randomized clinical trial. J Am Acad Dermatol 67: 226-32.
11. Carli L, Montecucco C, Rossetto O (2009) Assay of diffusion of different botulinum neurotoxin type a formulations injected in the mouse leg. Muscle Nerve 40: 374–80.
12. Roggenkämper P, Jost WH, Bihari K, Comes G, Grafe S (2006) Efficacy and safety of a new Botulinum Toxin Type A free of complexing proteins in the treatment of blepharospasm. J Neural Transm 113: 303–12.
13. Sattler G, Callander MJ, Grablowitz D, Walker T, Bee EK, Rzany B, et al. (2010) Noninferiority of incobotulinumtoxinA, free from complexing proteins, compared with another botulinum toxin type A in the treatment of glabellar frown lines. Dermatol Surg 36 (Suppl 49): 2146-54.
14. Trindade de Almeida AR, Marques E, de Almeida J, Cunha T, Boraso R (2007) Pilot study comparing the diffusion of two formulations of botulinum toxin type A in patients with forehead hyperhidrosis. Dermatol Surg 33: S37-43.
15. Hexsel D, Hexsel C, Siega C, Schilling-Souza J, Rotta FT, Rodrigues TC (2013) Fields of effects of 2 commercial preparations of botulinum toxin type A at equal labeled unit doses: A double-blind randomized trial. JAMA Dermatol. 2013 Oct 9. doi: 10.1001/jamadermatol.2013.6440.
16. Kerscher M, Roll S, Becker A, Wigger-Alberti W (2012) Comparison of the spread of three botulinum toxin type A preparations. Arch Dermatol Res 304: 155-61.
17. Brodsky MA, Swope DM, Grimes D (2012) Diffusion of botulinum toxins. Tremor Other Hyperkinet Mov (N Y) 2. pii: tre-02-85-417-1.
18. Shetty MK; IADVL Dermatosurgery Task Force (2008) Guidelines on the use of botulinum toxin type A. Indian J Dermatol Venereol Leprol 74: S13-22.
19. www.merriam-webster.com.
20. 7. Ramirez-Castaneda J, Jankovic J, Comella C, Dashtipour K, Fernandez HH, Mari Z (2013) Diffusion, spread, and migration of botulinum toxin. Mov Disord 28: 1775–83.
21. Carli L, Montecucco C, Rossetto O (2009) Assay of diffusion of different botulinum neurotoxin type a formulations injected in the mouse leg. Muscle Nerve 40: 374–80.
22. Cavallini M, Cirillo P, Fundarò SP, Quartucci S, Sciuto C, Sito G, et al. (2014) Safety of botulinum toxin A in aesthetic treatments: a systematic review of clinical studies. Dermatol Surg 40: 525-36.
